<DOC>
	<DOCNO>NCT02204644</DOCNO>
	<brief_summary>A study observe efficacy safety Flumatinib v Imatinib first line treatment patient newly diagnose chronic phase chronic myelogenous leukemia . Randomized , Open Label , Control</brief_summary>
	<brief_title>The Study Efficacy Safety Flumatinib v Imatinib First Line Treatment Patients With CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Men woman age 1875 yearold 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 3 . Philadelphia chromosomepositive chronic myeloid leukemia chronic phase ( Ph + CPCML ) within 6 month diagnosis 4 . Adequate organ function 1. receive TKIs drug treatment enrollment 2 . Central nervous system leukemia 3 . Previous antiCML therapy two week ( hydroxyurea , except anagrelide ) surgery ( include hematopoietic stem cell transplantation ) 4 . Cardiac dysfunction 5 . Previous splenectomy 6 . History congenital acquire bleed disorder unrelated CML 7 . Previous malignancy except CML 8 . Acute chronic liver severe kidney disease unrelated CML 9 . Pregnant , breastfeeding , child bear potential fail take effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>